Slide 1: Investor Presentation
Investor Presentation Sight Sciences May 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act o
Slide 3: Sight Sciences Mission
Sight Sciences Mission [[ Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care — empowering people to keep seeing. |3
Slide 4: A Glimpse Ahead
A Glimpse Ahead 1 2 3 Innovation leader in Near-term catalyst Strong balance sheet supports two large, growing, expected in TearCare significant investments in R&D underserved markets market access pipeline, clinical and commercial infrastructure 4 5 Healthy gross margin and The transformation of di
Slide 5: The Path to Early Intervention
The Path to Early Intervention A strategic roadmap to transform eyecare for glaucoma and dry eye patients by reducing patient burden, slowing disease progression, and improving outcomes. IDENTIFY EMBRACE SHIFT Identify patients who Embrace intervention as a better Shift the care continuum to can ben
Slide 6: Glaucoma
EZ — Glaucoma —
Slide 7: Glaucoma: Large + Underserved Markets
Glaucoma Leading cause of irreversible blindness Predominantly managed with daily (behind cataracts)1 eye drops (compliance often poor)2 Normal Mild Moderate Severe Large + Underserved Markets $6.0 BILLION addressable U.S. market3 >4 MILLION U.S. patients diagnosed with Glaucoma1 ¹ Source: Market Sc
Slide 8: Primary Open-Angle Glaucoma (POAG)
Primary Open-Angle Glaucoma (POAG) 01 Drain Cover (trabecular meshwork): allows excess aqueous fluid to enter drainage system THE CONVENTIONAL OUTFLOW PATHWAY IS AN IMPORTANT FOCAL POINT IN TREATING POAG, THE MOST COMMON FORM OF GLAUCOMA. 02 Sink Pipe (Schlemm’s Canal): POAG is similar to a clog in
Slide 9: Effective + Intuitive Intervention
OUR FLAGSHIP TECHNOLOGY SURGICAL GLAUCOMA Effective + Intuitive Intervention Comprehensive treatment of diseased conventional outflow pathway Leading clinical trial and registry results: ROMEO, GEMINI, AAO IRIS® Registry >300K Procedures Performed1 Offering a comprehensive intervention that drives l
Slide 10: OMNI Comprehensively Treats the Conventional Outflow Pathway
OMNI Comprehensively Treats the Conventional Outflow Pathway Minimally Invasive + Efficacious A comprehensive procedure enabled by the OMNI® Surgical System to help restore natural outflow in the eye with up to 360° treatment of all three areas of resistance* in the conventional outflow pathway * Tr
Slide 11: OMNI is Proven with Robust Clinical Evidence & Broad FDA Indication
OMNI is Proven with Robust Clinical Evidence & Broad FDA Indication OMNI is the most comprehensive implant-free Minimally Invasive Glaucoma Surgery (MIGS) technology, designed to effectively treat the full spectrum of primary open-angle glaucoma (POAG)1 OMNI is the only MIGS device with an FDA indic
Slide 12: Consistent Efficacy of OMNI in Combination Cataract and Standalone Clinical Trials
Consistent Efficacy of OMNI in Combination Cataract (CC) and Standalone (SA) Clinical Trials COMBINATION CATARACT STANDALONE GEMINI ROMEO Elevated IOP CC ROMEO Elevated IOP SA TREY SA (12 Months)* (24 Months) (24 Months) (11 Months)* 25 25 25 25 IOP (mmHg) IOP (mmHg) 20 23.8 20 21.7 20 22.1 20 21.7
Slide 13: OMNI Addresses All Six MIGS POAG Categories
OMNI Addresses All Six Minimally Invasive Glaucoma Surgery (MIGS) POAG Categories Allows surgeons to customize treatment STANDALONE MIGS $5B Opportunity >85% of POAG Eyes 1 1 COMBINATION CATARACT MIGS $1B Opportunity 1 <15%1 of POAG Eyes MARKET OPPORTUNITY1 MILD DISEASE MODERATE DISEASE ADVANCED DIS
Slide 14: Large and Unmet Clinical Need for Standalone MIGS
Large and Unmet Clinical Need for Standalone MIGS Combination Cataract Standalone <15% of POAG eyes1, >90% of MIGS procedures2 >85% of POAG eyes¹, <10% of MIGS procedures² Established, growing market Large, underserved patient population Benefits from inherent IOP-lowering effect of cataract surgery
Slide 15: MIGS for the Pseudophakic Patient
MIGS for the Pseudophakic Patient The Glaucoma Patient Journey1 Cataract Zone of unmet Advanced Glaucoma +/- MIGS clinical need Filtration Diagnosis Now a candidate for cataract Continues to progress until it Patient diagnosed with surgery, which may or may not Pseudophakic POAG Patients needs to be
Slide 16: Standalone Market Development is Underway
Standalone Market Development is Underway Claims data indicate increasing usage of codes associated with OMNI1 for billing of standalone procedures OMNI technology meets enhanced efficacy and safety Market development efforts to expand MIGS both in needs for standalone procedures combination catarac
Slide 17: Surgical Glaucoma Pipeline
Surgical Glaucoma Pipeline DEVELOPING COMPREHENSIVE BEST-IN-CLASS PORTFOLIO Implantable Suprachoroidal Sustained Release Canalicular Implant (MIGS)* Pharmaceutical (Rx)* Scaffold (MIGS)* CURRENT PRODUCTS IN THE PIPELINE 17 *This pipeline product is under development and is not commercially available
Slide 18: Dry Eye Disease
EZ — Dry Eye Disease was
Slide 19: Dry Eye Disease: Large + Underserved Markets
Dry Eye Disease Linked to screen time, age (postmenopausal Predominantly managed with daily women, men 50+), systemic medication use eye drops (compliance often poor)1 Normal Mild Moderate Severe Large + Underserved Markets ~$3.0 billion addressable U.S. market2 >13 million U.S. patients diagnosed w
Slide 20: Overview: Tears and Meibomian Gland Disease (MGD)
Overview: Tears and Meibomian Gland Disease (MGD) TEAR FILM ANATOMY • Tears consist of three layers • Outermost layer consists of oily substance called meibum Coats and protects inner layers Prevents premature evaporation MEIBOMIAN GLANDS • Healthy meibomian glands release liquid meibum with eac
Slide 21: A new order of care
A new order of care Effective intervention shouldn’t wait, because atrophy is irreversible1-3 Providers can intervene sooner with the power to preserve TearCare® targets the root cause of MGD: CATEGORY 1 obstructed glands4 OTC/Compresses TearCare® has been proven clinically superior to Restasis/cycl
Slide 22: ~$3.0 Billion Core MGD Opportunity
~$3.0 Billion Core MGD Opportunity U.S. patients diagnosed with Dry Eye Disease (DED)¹ million1 Up to 86% of DED is associated with poor tear quality due to meibomian gland disease (MGD) 1,2 million U.S. MGD patients1,2 Targeted patients estimated to need 1.3 procedures per year3 billion core opport
Slide 23: Dry Eye Disease (DED): Large + Underserved Disease State
Dry Eye Disease (DED): Large + Underserved Disease State The current market is • Existing dry eye treatments mostly focus on increasing dominated by eyedrops tear volume in aqueous deficient patients that do not address the • No interventional standard of care for treatment of MGD underlying causes
Slide 24: Targeted + Intuitive Intervention
OUR TECHNOLOGIES DRY EYE Targeted + Intuitive Intervention Comprehensive therapy to treat diseased meibomian glands Leading Clinical Trial Results: SAHARA, OLYMPIA >65K Procedures Performed1 Offering a comprehensive therapy intervention that drives leading clinical outcomes for evaporative dry eye d
Slide 25: TearCare: Designed to Treat MGD
TearCare: Designed to Treat MGD TearCare is the only interventional, open-eye, thermal-activated restorative gland expression therapy (TARGET) designed to preserve and restore gland functionality 01 Application 02 Therapy 03 Expression Thin, wearable SmartLids® Precise, consistent, software- Compreh
Slide 26: SAHARA RCT
SAHARA RCT 6-MONTH PUBLICATION: CLINICAL OPHTHAMOLOGY DATE: DEC 2023 Randomized Controlled Trial comparing TearCare and Restasis®1 Superiority + Durability2 + Head-to-Head Study TearCare vs Restasis1 + Large Trial (N=345) + Randomized + Masked ¹ Restasis is a trademark of Allergan an AbbVie company
Slide 27: SAHARA RCT: Results
SAHARA RCT: Results TearCare Superior to Restasis in Tear Breakup Time Improvement TearCare Results at 6 Months Absolute Change from Baseline at Each Time Point • Superior to Restasis1, 2 in tear break-up time (TBUT) • Non-inferior to Restasis in OSDI3 TearCare Restasis Crossover • Significant impro
Slide 28: TearCare Strategy: Targeted + Scalable Growth
TearCare Strategy: Targeted + Scalable Growth Actively Engaging in Pursuit of Equitable Market Access With the power of TearCare, we can: • Improve the lives of U.S. MGD patients • Scale commercial resources with market access wins • Target ~9,500 physicians identified as most likely to adopt MGD tr
Slide 29: What's Next
EZ — What’s Next —
Slide 30: Annual Revenue and Gross Margin %
Annual Revenue and Gross Margin % SGHT DRY EYE SURGICAL GLAUCOMA GROSS MARGIN % Revenue CAGR FY20 to FY24 83% 85% 85% 82% $81.1 $79.9 67% $4.0 $71.3 $6.7 $5.7 FY25 Guidance $49.0 $74.3 $75.9 Revenue $70M - $75M¹ $70.0M - $2.5 $65.6 $75.0M1 Adj. OpEx² $101M - $105M¹ $27.6 $46.5 $1.6 FY24 Gross Margin
Slide 31: Strategic Value Creation Initiatives Represent Sustainable Growth Drivers
Strategic Value Creation Initiatives Represent Sustainable Growth Drivers Expand OMNI Utilization TearCare Access + Expansion • Engage with accounts post LCD clarity with • Generate eyecare provider engagement and pursue restrictions on multiple MIGS coverage and equitable reimbursement • Certify ne
Slide 32: Why Now?
Why Now? 1 2 3 Innovation leader in Near-term catalyst Strong balance sheet supports two large, growing, expected in TearCare significant investments in R&D underserved markets market access pipeline, clinical and commercial infrastructure 4 5 Strong gross margin and The transformation of discipline
Slide 33: Thank you!
Thank you! If you have any questions, please contact investor.relations@sightsciences.com © Sight Sciences and/or certain of its affiliates, All rights reserved. Sight Sciences, the Sight Sciences logo, OMNI, SION, TearCare, and TruSync are trademarks or registered trademarks of Sight Sciences. | 33